You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

VENE+RITU

Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)      Intent: Palliative
Regimen Category: Evidence-informed
Funding:
Exceptional Access Program
    Treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) according to clinical criteria
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Venetoclax - Relapsed Chronic Lymphocytic Leukemia
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Venetoclax - Relapsed Chronic Lymphocytic Leukemia

You might also be interested in